Dehydroandrographolide

Catalog No.S3807 Batch:S380702

Print

Technical Data

Formula

C20H28O4
Molecular Weight 332.43 CAS No. 134418-28-3
Solubility (25°C)* In vitro DMSO 66 mg/mL (198.53 mM)
Ethanol 33 mg/mL (99.26 mM)
Water Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Dehydroandrographolide, isolated from Andrographis paniculata (Burm. F.) Nees (Chuan-xin-lian), is a novel TMEM16A inhibitor and possesses multiple pharmacological activities, including anti-inflammation, anti-cancer, anti-bacterial, anti-virus and anti-hepatitis activity.
Targets
TMEM16A [1]
In vitro Dehydroandrographolide inhibits TMEM16A chloride currents in Fisher rat thyroid (FRT) cells that are transfected stably with human TMEM16A and in TMEM16A-overexpressed SW620 cells but does not alter cystic fibrosis transmembrane conductance regulator (CFTR) chloride currents. Further functional studies show that dehydroandrographolide suppresses the proliferation of SW620 cells in a dose- and time-dependent manner using MTT assays. Dehydroandrographolide significantly inhibits migration and invasion of SW620 cells as detected by wound-healing and transwell assays. Moreover, treatment of SW620 cells with dehydroandrographolide leads to a decrease in TMEM16A protein levels but has no effect on TMEM16A mRNA levels[1]. Dehydroandrographolide induces autophagy in human oral cancer cells by modulating p53 expression, activating JNK1/2, and inhibiting Akt and p38. Dehydroandrographolide is an iNOS inhibitor and an antiinflammatory and antiviral agent[2].
In vivo Administration of dehydroandrographolide effectively suppresses the tumor formation in the oral carcinoma xenograft model in vivo[2].

Protocol (from reference)

Cell Assay:[1]
  • Cell lines

    SW620 cells

  • Concentrations

    5, 10, 20, 40 or 80 μM

  • Incubation Time

    24 h

  • Method

    Cells (2 × 104 cells/ml) in the absence or presence of DP at different concentration are incubated for 24 h in 24-well tissue culture plates. At the end of the incubation period, the culture medium is removed and cells are washed with phosphate-buffered saline (PBS pH 7.4) and the cells are photographed under an inverted microscope at 100 × magnification.
Animal Study:[2]
  • Animal Models

    5–6 week male BALB/c nude mice

  • Dosages

    40 or 100 mg/kg

  • Administration

    oral

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.